Krystal Biotech, INC Form 4 insider transactions

CEO Krish S. Krishnan reports multiple transactions involving Krystal Biotech stock, including acquisitions from performance stock unit and restricted stock unit vesting, and disposals for tax withholding.

Suma Krishnan, President of R&D at Krystal Biotech, sold shares of the company's common stock on December 13, 2024, under a pre-arranged 10b5-1 trading plan.

Krystal Biotech's CEO, Krish S. Krishnan, and his spouse, Suma M. Krishnan, sold shares of the company's common stock on December 13, 2024, under pre-arranged 10b5-1 trading plans.

Suma Krishnan, a Director and Officer at Krystal Biotech, sold shares of common stock on September 12, 2024, under a pre-arranged 10b5-1 trading plan.

Krystal Biotech's CEO, Krish Krishnan, and his spouse executed sales of common stock under pre-arranged Rule 10b5-1 trading plans.

Director Dino A. Rossi of Krystal Biotech, Inc. reports a gift of 5,000 common stock shares to a charitable donor-advised fund on September 13, 2024.

Director Julian S. Gangolli of Krystal Biotech, Inc. reports the acquisition of stock options.

Director Daniel Janney of Krystal Biotech, Inc. was granted stock options to purchase 5,000 shares of common stock on June 30, 2024.

Director Christopher Mason of Krystal Biotech, Inc. was granted stock options to purchase 5,000 shares of common stock on June 30, 2024.

Catherine Mazzacco, a director at Krystal Biotech, Inc., acquired 5,000 stock options on June 30, 2024, vesting monthly over one year.

Director Everett Rand Sutherland of Krystal Biotech, Inc. was granted 5,000 stock options on June 30, 2024, vesting monthly over one year.

Director Dino A. Rossi acquired stock options in Krystal Biotech, Inc. on June 30, 2024.

Suma Krishnan, a Director and Officer at Krystal Biotech, sold shares of common stock on June 11, 2024, under a pre-existing 10b5-1 trading plan.

Krystal Biotech's CEO, Krish Krishnan S, reports the sale of company shares on June 11, 2024, under a pre-existing 10b5-1 trading plan, which has now terminated.

Director Julian S. Gangolli exercised stock options and sold shares of Krystal Biotech (KRYS) on May 20, 2024.

Suma Krishnan, a director and officer at Krystal Biotech, sold shares of common stock on March 11, 2024, under a pre-arranged 10b5-1 trading plan.

Krystal Biotech's CEO, Krish Krishnan S, and his spouse sold shares of the company's common stock on March 11, 2024, under pre-arranged 10b5-1 trading plans.

Kathryn Romano, Chief Accounting Officer of Krystal Biotech, Inc., reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

Kathryn Romano, Chief Accounting Officer of Krystal Biotech, Inc., executed multiple transactions involving the exercise of stock options and the sale of common stock on February 28, 2024, under pre-arranged Rule 10b5-1 trading plans.

Suma Krishnan, President of R&D at Krystal Biotech, reports the vesting of performance stock units (PSUs) and related tax withholding transactions.

Krystal Biotech's CEO, Krish Krishnan, reports the vesting of performance stock units (PSUs) and restricted stock units (RSUs), along with associated tax withholding and new grants.

Suma Krishnan, President of R&D at Krystal Biotech, reports the disposition of 2,353 shares for tax withholding purposes following the vesting of restricted stock.

Krystal Biotech's CEO, Krish Krishnan, reports the surrender of shares for tax withholding upon vesting of restricted stock.

Kathryn Romano, Chief Accounting Officer of Krystal Biotech, Inc., reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.